Search company, investor...
Ocugen company logo


Founded Year



Loan | IPO

Total Raised


About Ocugen

Ocugen is a Malvern, Pennsylvania-based ophthalmology company developing a clinical pipeline of therapies that address rare and underserved ocular disorders.

Headquarters Location

5 Great Valley Parkway Suite #160

Malvern, Pennsylvania, 19355,

United States


Missing: Ocugen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ocugen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Ocugen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ocugen is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Ocugen Patents

Ocugen has filed 9 patents.

The 3 most popular patent topics include:

  • Amines
  • Autoimmune diseases
  • Beta blockers
patents chart

Application Date

Grant Date


Related Topics




Orthopedic surgical procedures, Joints, Skeletal system, Biomaterials, Extracellular matrix proteins


Application Date


Grant Date



Related Topics

Orthopedic surgical procedures, Joints, Skeletal system, Biomaterials, Extracellular matrix proteins



Latest Ocugen News

Seven Amarin directors resign after Sarissa proxy win

Mar 7, 2023

Seven Amarin directors resign after Sarissa proxy win Plus: Ocugen expands Quan Vu’s role to CBO and CFO, and updates from BPGbio and MediWound By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst March 7, 2023 1:45 AM UTC Seven independent board members at Amarin Corp. plc (NASDAQ:AMRN) resigned Monday following the victory of activist investor Sarissa Capital Management in a proxy contest against the company’s board last week. The resigning board members are Adam Berger, Erin Enright, Geraldine Murphy, Kristine Peterson, Murray Stewart, Jan van Heek and Alfonso “Chito” Zulueta. Last week, Amarin shareholders voted to elect all seven of Sarissa’s board nominees and remove Per Wold-Olsen as chairman. An estimated 80% of shareholders voted in support of Sarissa. Ocular gene and cell therapies and vaccines company Ocugen Inc. (NASDAQ:OCGN) expanded the role of CBO Quan Vu to include CFO. Vu joined Ocugen last month, before which he was COO and CBO at 180 Life Sciences Corp. (NASDAQ:ATNF)... BCIQ Company Profiles

Ocugen Frequently Asked Questions (FAQ)

  • When was Ocugen founded?

    Ocugen was founded in 2013.

  • Where is Ocugen's headquarters?

    Ocugen's headquarters is located at 5 Great Valley Parkway, Malvern.

  • What is Ocugen's latest funding round?

    Ocugen's latest funding round is Loan.

  • How much did Ocugen raise?

    Ocugen raised a total of $19.73M.

  • Who are the investors of Ocugen?

    Investors of Ocugen include Paycheck Protection Program, Histogenics, Abdi Ibrahim, JSC Lancaster Group, Frank Leo and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.